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Abstract
Background: In Ethiopia, malaria is caused by Plasmodium falciparum and Plasmodium vivax, and anti-malarial drug
resistance is the most pressing problem confronting control of the disease. Since co-infection by both species of
parasite is common and sulphadoxine-pyrimethamine (SP) has been intensively used, resistance to these drugs has
appeared in both P. falciparum and P. vivax populations. This study was conducted to assess the prevalence of
anti-malarial drug resistance in P. falciparum and P. vivax isolates collected at a rural hospital in southern Ethiopia.
Methods: A total of 1,147 patients with suspected malaria were studied in different months across the period
2007-2009. Plasmodium falciparum dhfr and dhps mutations and P. vivax dhfr polymorphisms associated with
resistance to SP, as well as P. falciparum pfcrt and pfmdr1 mutations conferring chloroquine resistance, were
assessed.
Results: PCR-based diagnosis showed that 125 of the 1147 patients had malaria. Of these, 52.8% and 37.6% of
cases were due to P. falciparum and P. vivax respectively. A total of 10 cases (8%) showed co-infection by both
species and two cases (1.6%) were infected by Plasmodium ovale. Pfdhfr triple mutation and pfdhfr/pfdhps quintuple
mutation occurred in 90.8% (95% confidence interval [CI]: 82.2%-95.5%) and 82.9% (95% CI: 72.9%-89.7%) of P.
falciparum isolates, respectively. Pfcrt T76 was observed in all cases and pfmdr1 Y86 and pfmdr1 Y1246 in 32.9%
(95% CI: 23.4%-44.15%) and 17.1% (95% CI: 10.3-27.1%), respectively. The P. vivax dhfr core mutations, N117 and
R58, were present in 98.2% (95% CI: 89.4-99.9%) and 91.2% (95% CI: 80.0-96.7%), respectively.
Conclusion: Current molecular data show an extraordinarily high frequency of drug-resistance mutations in both P.
falciparum and P. vivax in southern Ethiopia. Urgent surveillance of the emergence and spread of resistance is thus
called for. The level of resistance indicates the need for implementation of entire population access to the new
first-line treatment with artemether-lumefantrine, accompanied by government monitoring to prevent the
emergence of resistance to this treatment.
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Malaria is the vector-borne disease with the highest
impact on the world’s human population. In 2008, there
were an estimated 243 million cases, leading to nearly
863,000 malaria-related deaths [1]. Although malaria-
endemic areas are mainly restricted to tropical and sub-
tropical regions at present, several models nonetheless
project the geographical expansion of potential malaria
transmission over the next few decades, along with
more substantial changes later in the century [2].
Approximately 90% of clinically manifest infections of
and practically all deaths from malaria are caused by
Plasmodium falciparum. Ranking second in importance
is Plasmodium vivax, which accounts for nearly 10% of
global malaria incidence. Roughly 90% of all malaria
cases occur in tropical Africa [3].
Approximately 52 million people in Ethiopia are con-
sidered to be at risk of the disease [4]. While 4 to 6 mil-
lion clinical malaria cases are annually reported by the
country’s health facilities, the real number is estimated
to be as high as 10 to 15 million [5]. The major Plasmo-
dium species causing malaria in Ethiopia are P. falci-
parum (about 60% of cases) and P. vivax (about 40% of
cases), with the former being the cause of the most
severe clinical manifestations and most deaths [6-8].
Malaria transmission follows a seasonal pattern (Sep-
tember-November), depending on the altitude and rainy
season [7,9]. Epidemic malaria is frequent [10], particu-
larly in the highlands (1,000-2,000 m above sea level).
Anti-malarial drug resistance in P. falciparum and P.
vivax is the most pressing problem confronting malaria
control in many endemic countries [11,12]. Plasmodium
falciparum has developed resistance to a series of drugs,
and P. vivax is resistant to chloroquine (CQ) and not
primaquine-tolerant (PQ) [13,14]. Furthermore, in coun-
tries where intensive use has been made of sulphadox-
ine-pyrimethamine (SP), resistance to these drugs has
appeared in P. vivax populations [15-20], though some
authors view this as being a sign of innate resistance to
sulphadoxine in such parasites [21].
Current studies report high rates of therapeutic failure
(72%) in some areas of Ethiopia [22], due to the pre-
sence of SP resistance in the two principal species. In
2004, artemether-lumefantrine (AL) (Coartem
®)w a s
introduced into the country as a first-line treatment,
and the national guidelines have since prescribed this
drug for uncomplicated malaria [4]. Even so, not every-
one is benefiting from this treatment because 85% of
the population live in rural areas where access to basic
health care is severely limited.
In general, the presence of high resistance to SP has
stopped it from being used as a treatment in African
endemic countries, and so nowadays it is only used, in
combination with insecticide-treated mosquito nets, for
Intermittent Preventive Treatment (IPT) in pregnant
women and in areas where it has been given to children
under five years of age has provided encouraging results
[23].
The study of point mutations (Single Nucleotide Poly-
morphisms - SNPs) in molecular markers is an extre-
mely useful epidemiological tool, which enables the
emergence and spread of mutant parasites to be moni-
tored. Analyses of different molecular markers of resis-
tance are currently used, namely: the T76 point
mutation in the P. falciparum pfcrt gene; the Y86, F184,
C1034, N1042 and Y1246 point mutations in the
pfmdr1 gene [24]; the L164, N/T108, I51 and R59 point
mutations in the pfdhfr gene; and the G437 and G581,
A/F436, E540 and S613 point mutations in the pfdhps
gene [12,24-28].
Plasmodium vivax resistance to SP is associated with
mutations that appear in the homologous genes, pvdhfr
(N117, R58 and T117) and pvdhps (G383, G553)
[17,18]. Mutations in pvdhfr have been implicated in
resistance to pyrimethamine in vivo [29]. Furthermore,
it seems that pvdhfr mutations at residues 117 and 58
have been observed to arise first when drug pressure is
applied [17,18,30]. The double and triple mutations,
N117/R58 and N117/R58/L57, are associated with
delayed parasite clearance following SP treatment [17]
and with therapeutic failure in many regions of south-
east Asia [17,31,32], Iran [30], Pakistan [33], India [34],
Colombia [28] and Madagascar [35].
However, the appearance of different combinations of
L57/R58/N117/G383/G553 mutations in both the pvdhfr
and pvdhps genes has been associated with SP treatment
f a i l u r eo n l yi np a t i e n t si n f e c t e db yP. vivax and not in
those co-infected by both species [36,37] in which no
mutations have been found in the orthologous genes of
P. falciparum.
This study sought to determine the following: the pre-
valence of P. falciparum and P. vivax in patients with
clinically suspected malaria, attending the Gambo Gen-
eral Rural Hospital in Ethiopia; and the prevalence of
mutations in genes involved in resistance to different
anti-malarial drugs, based on samples collected in differ-
ent months across the period 2007-2009.
Methods
Study site and biological samples
The Gambo General Rural Hospital is situated in the
province of West Arsi, Ethiopia, 245 kilometres south-
east of the capital, Addis Ababa (Figure 1), at an altitude
of 2,250 metres (approximately 7,382 feet) above sea
level. The hospital provides daily health care and covers
nine peripheral health centres serving 23 villages, with a
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dering areas, lying at lower altitudes.
The study was conducted during different calendar
months across the period 2007-2009. At the hospital, a
total of 1,147 blood samples were collected from
patients (age range, 1 month to 75 years) with clinically
suspected malaria (see Table 1). Two capillary blood
specimens were taken from each patient, one for confir-
mation of Plasmodium infection by microscopic obser-
vation of thin and thick Giemsa-stained blood films, and
the other on filter paper (Whatman
© 3M M )f o rm o l e -
cular assay.
DNA extraction was performed using commercial kits
(Speedtools tissue DNA Extraction Kit, Biotools), and
Plasmodium species were subsequently confirmed by
Seminested-Multiplex PCR [38]. The nested PCR-RFLP
technique was used to analyse: codons 76 of pfcrt,8 6
and 1246 of pfmdr1, 51, 59, 108 and 164 of pfdhfr and
436, 437, 540 and 581 of pfdhps from samples infected
by P. falciparum [39]; and codons pvdhfr 57, 58 and 117
and pvdhps 383 and 553 from samples infected with P.
vivax. The laboratory conditions and restriction enzymes
have been described elsewhere [17,18,30]. As in other
resistance studies [40], genes that showed mixed wild-
type and mutant alleles were deemed to be mutant only
when the amplification fragment was more intense for
the latter. The study protocol was approved by the
research review boards of the Institute of Health Carlos
III (Madrid, Spain) and Gambo General Rural Hospital.
Study participants with microscopy-confirmed malaria
infection were treated in accordance with Ethiopian
national guidelines [4,5]. A descriptive analysis was per-
formed and estimates of prevalence along with their
95% confidence intervals (CIs) were obtained, using the
method described by Newcombe [41].
Results
Molecular results
The presence of parasites was confirmed by Seminested-
Multiplex-PCR in all the samples. Of the 1,147 samples,
a total of 125 (10.9%; 95% CI: 9.2-12.8%) were shown to
be infected by Plasmodium sp., which broke down as
follows: P. falciparum,6 6( 5 . 8 % ;9 5 %C I :4 . 5 - 7 . 3 % ) ;P.
vivax, 47 (4.1%; 95% CI: 3.1-5.5%); P. falciparum and P.
vivax combined, 10 (0.9%; 95% CI: 0.4-1.6%); and Plas-
modium ovale, 2 (0.2%; 95% CI: 0.03-0.7%). The preva-
lence of Plasmodium species in infected cases (n = 125)
is shown in Table 2.
The frequencies of mutations and the combinations of
t h e s ei nt h eg e n e si n v o l v e di na n t i - m a l a r i a ld r u g
Gambo
A B
Figure 1 Gambo location in Ethiopia. The left figure (1 A) displays the location of Gambo on the map of Ethiopia (black star). The right figure
(1 B) shows the satellite image of Gambo. Source of maps: 1 A: http://www.mara.org.za/; 1 B: Google Maps.
Table 1 Number of samples collected by year of study.
Year Months No of Months Samples
2007 Nov-Dec 2 175
2008 Jan-May 5 432
2009 Feb-May 4 540
Total months: 11 Total samples: 1,147
(Nov: November/Dec: December/Jan: January/Feb: February).
Table 2 Prevalence of Plasmodium species in infected
patients (n = 125).
Infection n = 125 Frequency (%)
P. falciparum 66 52.8%
P. vivax 47 37.6%
P. ovale 2 1.6%
Mixta P. falciparum/P. vivax 10 8.0%
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Figure 2 respectively. Whereas all samples infected with
P. falciparum presented with the pfcrt T76 mutation (95
CI: 95.1-100%), 32.9% (95% CI: 23.4-44.1%) and 17.1%
(95% CI: 10.3-27.1%) of samples infected with P. falci-
parum had the pfmdr1 Y86 and pfmdr1 Y1246 muta-
tions respectively.
As with pfcrt T76, all samples infected with P. falci-
parum showed a 100% prevalence of mutation at pfdhfr
N108. Only one case (1.3%; 95% CI: 0.2-7.1%), however,
presented with the mutation at pfdhfr L164. The pfdhfr
I51 and R59 mutations, responsible for modulating
resistance to pyrimethamine, appeared in 97.4% (95%
CI: 90.9-99.3%) and 90.8% (95% CI: 82.2-95.5%) of cases
respectively. The triple I51/R59/N108 mutation was
observed in over 90% (95% CI: 82.2-95.5%) of cases
(Figure 2).
Insofar as the SNPs in pfdhps were concerned, none of
the samples had wild genotypes at the codons studied.
Both pfdhps A436 and pfdhps G581 mutations appeared
at low frequencies (18.4% [95% CI: 11.3-28.9%] and
14.5%, [95% CI: 8.3-24.1%] respectively) compared to
the pfdhps G437 and pfdhps E540 mutations, which
appeared in 92.1% (95% CI: 83.8-96.3%) and 68.4% (95%
CI: 57.3-77.8%) of cases respectively. The pfdhps double
mutation, G437/E540, appeared in 84.2% (95% CI: 74.4-
90.7%) of cases.
The pfdhfr/pfdhps quadruple and quintuple mutations,
N108/I51/R59+G437 and N108/I51/R59+G437/E540
(both associated with therapeutic failure of SP), dis-
played a prevalence of over 80% (95% CI: 70-87.7%)
among cases infected by P. falciparum (Figure 2).
While 98.2% (95% CI: 89.4-99.9%) of samples infected
with P. vivax showed the N117 mutation at codon 117
of the pvdhfr gene, R58 appeared at codon 58 in 91.2%
(95% CI: 80.0-96.7%) of cases. The pvdhfr double muta-
tion, N117/R58, was observed in most cases of P. vivax
infection (91.2%; 95% CI: 80.0-96.7%) but no case dis-
played mutation at codon 57 (95% CI: 0-7.9%).
With respect to the pvdhps gene, mutation was found
at codon 553, with a prevalence of 3.5% (95% CI: 0.6-
13.2%) and appeared at the same frequency (3.5%; (95%
CI: 0.6-13.2%) in combination with the double N117/
R58 mutation (Table 4).
All cases that were co-infected by both species (n =
10) and presented with mutations in pfdhfr/pfdhps (I51/
R59/N108, 80% [95% CI: 49.0-94.3%]; N108/I51/R59
Table 3 Prevalence of mutations conferring resistance to
chloroquine and sulphadoxine-pyrimethamine in
Plasmodium falciparum (n = 76).
Gene Locus n = 76 Mutation (%)
pfcrt 76 76 (100%)
pfmdr1 86 25 (32.9%)
pfmdr1 1246 13 (17.1%)
pfdhfr 51 74 (97.4%)
pfdhfr 59 69 (90.8%)
pfdhfr 108 76 (100%)
pfdhfr 164 1 (1.3%)
pfdhps 436 14 (18.4%)
pfdhps 437 70 (92.1%)
pfdhps 540 52 (68.4%)
pfdhps 581 11 (14.5%)
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Figure 2 Prevalence of grouped pfdhfr/pdhps mutant alleles in P. falciparum linked to sulphadoxine-pyrimethamine treatment failure
(n = 76).
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+G437/E540, 70% [95CI: 39.7-89.2]), also introduced the
double mutation, N117/R58, (100%; 95% CI: 72.3-100%)
in pvdhfr.
Discussion
In areas where P. falciparum and P. vivax co-exist, para-
site-specific diagnosis and choice of effective treatment
is crucial to prevent the emergence and spread of resis-
tance. In malaria-endemic areas, the occurrence of
P. falciparum/P. vivax co-infection is frequent and it is,
therefore, common for P. vivax to have been exposed to
treatment with SP.
In Ethiopia, not only are there wide interregional dif-
ferences in the endemicity and transmission of malaria,
but there is also a significant lack of information on the
effectiveness of anti-malarial drugs. In 1999, the CQ
treatment failure rate in the first two weeks still stood at
88% in the centre of the country [42]. In 2005, SP thera-
peutic failure within two to four weeks of follow-up was
36% and 72% respectively. In this same year, however,
treatment with AL yielded an appropriate clinical and
parasitological response of 99% [22].
With regard to the prevalence of species, a decrease of
P. falciparum mono-infection and an increase of P.
vivax mono-infection was observed in contrast to other
results obtained by other studies previously conducted
in Ethiopia [6,7,43,44]. The predominant species was P.
falciparum, which appeared in approximately 53% of
cases, followed by P. vivax with a prevalence higher
than 30%, and a small proportion cases of co-infection
by both species. In addition, two cases of infection by
Plasmodium ovale were detected. This finding is rather
singular; in that P. ovale has never been previously
described in Ethiopia, and might be accounted for by
the migration process from the western side of the con-
tinent to this country, or people returning after having
gone to work in other areas of Africa with prevalence
of P. ovale. In the future, more studies about the
prevalence of malaria species should be performed in
Ethiopia, to know the factors are influencing in these
changes of prevalence.
As with other studies in which high rates of therapeu-
tic failure of CQ and SP have been detected, our results
likewise show a high prevalence of these mutations
linked to resistance in P. falciparum, particularly T76 in
pfcrt (responsible for resistance to CQ) and the triple
mutation in pfdhfr (responsible for treatment failure in
SP) (see Table 3 and Figure 2). Furthermore, the high
rate of the pfdhps double mutation, G437/E540, respon-
s i b l ef o rc o n f e r r i n gah i g hd e g r e eo fr e s i s t a n c et os u l -
phadoxine and for therapeutic failure to SP in the
presence of the triple mutation in pfdhfr, has resulted in
the pfdhfr/pfdhps quintuple mutation being present in
over 80% of cases. This corresponds to the low SP-treat-
ment efficacy rates registered in different regions of
Ethiopia [22] and confirms the need for AL to be made
available countrywide as the first-line treatment.
The pfcrt T76, pfmdr1 Y86 and pfmdr1 Y1246 muta-
tions are very useful molecular markers of CQ resistance
in areas where resistance rates are low to mild [45,46].
This study showed high to moderate prevalence of pfcrt
and pfmdr1 mutations, respectivel y ,t ob ec o n s i s t e n t
with low CQ efficacy in Ethiopia [42].
In the case of P. vivax, there was a high prevalence of
the pvdhfr R58 and pvdhfr N117 mutations. Further-
more, the pvdhfr double mutation, N117/R58, appeared
in 52 out of 57 cases infected by P. vivax (taking the
cases of P. falciparum co-infection into account), and 42
out of 47 cases infected by this species alone. The
pvdhps G553 mutation always appeared in combination
with pvdhfr double mutation R58/N117, resulting
pvdhfr/pvdhps R58/N117/G553 mutation in two cases of
P. vivax mono-infection. This finding could explain a
possible SP treatment failure in these patients, as has
been associated in other studies [36,37]. Yet pvdhfr
T117, L57, pvdhfr triple or pvdhfr/pvdhps quadruple
mutations were not in evidence, in the last case neither
in P. vivax mono-infection nor in P. vivax-P. falciparum
co-infection. Although these multiple mutations seem to
be necessary for in vivo resistance [17,18,43], this find-
ing nevertheless suggests widespread SP use, since the
pvdhfr mutations arise first under drug pressure
[17,18,43].
It should be taken into account that, when it comes to
combined P. falciparum/P. vivax infection, patients
should be treated with a blood schizonticide (for both
species) and a tissue schizonticide (for hepatic hypno-
zoites of P. vivax). In the past, SP was used as treatment
for P. falciparum. As a result, P. vivax came into contact
with the same treatment when it was present in mixed
infections, and mutations in different genes linked to SP
resistance have thus appeared in this species. The
Table 4 Prevalence of mutations conferring resistance
to sulphadoxine-pyrimethamine in Plasmodium vivax
(n = 57).
Gene Locus N = 57 Mutation (%)
pvdhfr R58 52 (91.2%)
pvdhfr L57 0 (0%)
pvdhfr N117 56 (98.2%)
pvdhfr T117 0 (0%)
pvdhfr R58/N117 52 (91.2%)
pvdhfr R58/N117/L57 0 (0%)
pvdhps G383 0 (0%)
pvdhps G553 2 (3.5%)
pvdhfr/pvdhps R58/N117/G553 2 (3.5%)
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accounted for, i.e., here, only the G553 mutation, impli-
cated in resistance to sulphadoxine and corresponding
to the G581 mutation in P. falciparum, displayed a very
low prevalence and appeared in the presence of the
pvdhfr double mutation, N117/R58. In contrast, the
G383 mutation, which corresponds to G437 in P. falci-
parum, was observed in neither case. This strengthens
the hypothesis that the asymmetric selection process of
mutations observed in P. falciparum is also applicable to
P. vivax [21].
Samples co-infected by these two species showed
mutations in either pfdhfr/pfdhps or pvdhfr,w h i c h
would explain why treatment for both these species of
Plasmodium could fail in such patients.
In view of the genotype results obtained, it would be
advisable for a study of therapeutic efficacy to be con-
ducted in this area, to ascertain whether the genotypic
are the same as the phenotypic data, i.e., whether the
parity mutation-resistance is produced in vivo.
Moreover, it would be advisable for future research to
verify whether there were mutations in genes (such as
atp6) related with resistance to artemisinin derivatives,
the use of which as an anti-malarial drug has spread in
Africa. Artemisinin-based combination therapy (ACT)
(for example, using Coartem
®) has come into use in
Ethiopia, though it is proving difficult to implement in
rural areas due to the continued use of drugs, such as SP
and CQ, in combination with other medication, a prac-
tice that continues to favour the expansion of resistance.
Conclusions
1. The prevalence of Plasmodium species is slightly dif-
ferent from the results obtained by other authors in pre-
vious studies conducted in Ethiopia, showing an increase
of vivax malaria cases and the presence of P. ovale for
the first time.
2. The prevalence of mutations linked to CQ and SP
resistance detected in P. falciparum and P. vivax in
southern Ethiopia is higher than expected.
3. Implementation of permanent surveillance of resis-
tance molecular markers as an epidemiological tool will
enable health professionals and authorities to be alerted
to the possible emergence and spread of resistance to
new lines of treatment, such as ACT.
4. It is essential that the entire population be provided
with access to new first-line treatment with ACT, which
should be given under government supervision to avoid
the drug being mismanaged and so prevent the emer-
gence of any new resistances.
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